|Bid||137.17 x 600|
|Ask||138.69 x 200|
|Day's Range||137.10 - 138.91|
|52 Week Range||96.93 - 138.91|
|PE Ratio (TTM)||51.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
View more earnings on CURE See more from Benzinga Focusing On An Alternative To S&P 500 ETFs A New ETF For Low Vol ETFs © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved....
Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.